NF2 and neurofibroma: sgRNAs suppressing NF2 were among the strongest drivers of both growth and selumetinib responses in our CRISPRi screening data (Fig. 3a), and NF2 loss was significantly increased in histological neurofibromas and MPNSTs from Group 1/2 versus Group 3 (Fig. 1a and Supplementary Fig. 1g).